Pain Control in Oral Mucositis According to the Severity Scale: A Narrative Literature Review

Authors
Category Systematic review
JournalJ. Clin. Med.
Year 2025
BACKGROUND: Oral mucositis (OM) is a painful and debilitating stomatitis that often arises following head and neck radiotherapy, chemotherapy, or stem cell transplant, leading to treatment delays and potential patient intervention interruption. The aim of this narrative review was to explore the modalities in the management of OM. When supported by evidence, treatment is customized according to its severity. METHOD: A literature search was performed using the PubMed database. The search strategy consists of keywords such as "pain management", "pain control", and "oral mucositis". Literature references from 1997 to 2024 were selected by the authors based on relevance to the current practice of oral mucositis pain management. RESULTS: Fourteen studies were included in this review. Interventions were classified into pharmacological and non-pharmacological modalities. In relation to pain measurement, for grade 1 OM, topical treatments are the primary recommendation. For grades 2 to 4, where pain is moderate to severe, systemic analgesia should be administered. Honey and oral care are beneficial for OM with grades 2 to 4. CONCLUSIONS: Effective management of OM should be tailored to the severity of the condition, incorporating both pharmacological and non-pharmacological strategies. While various modalities have shown promise in relieving symptoms and enhancing the quality of life, a multifaceted, patient-centered approach remains essential. Advancing high-quality clinical trials, particularly those evaluating non-pharmacological interventions will be crucial to expanding treatment options. Future efforts should focus on personalized therapies, integration of combination treatments, adoption of standardized pain assessment tools, and long-term outcome studies to improve clinical effectiveness and optimize patient care.
Epistemonikos ID: 367210fe56577662644f241392ddfb634f6aef17
First added on: Jul 13, 2025